Salbutamol effects on endurance athletes and screening for breathing limits
Official title: Physiological, Sensory and Ergogenic Effects of Salbutamol - Implications for Athletic Screening and β2 Agonist Use in Sport
Run by University of British Columbia · NCT07037511 · Data updated 2026-11-12
This study will test whether a common asthma inhaler, salbutamol, helps non-asthmatic endurance athletes who experience breathing limits during high-intensity exercise.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 55 Years |
| Sex | All |
| Enrollment | 64 (estimated) |
| Sponsor | University of British Columbia Academic / other |
| Locations | 1 site (Vancouver, British Columbia) |
| Status | Recruiting |
| Started | October 30, 2025 |
| Main results expected | December 31, 2029 |
| Study ends | December 31, 2030 |
| Registry record updated | March 13, 2026 |
| Trial ID | NCT07037511 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are non-asthmatic adult endurance athletes who currently train or compete, have V̇O2max >120% predicted, BMI 18–30 kg/m2, no recent smoking or cardiopulmonary disease, and can attend in-person testing.
✕Probably not a fit
Smokers, people with cardiopulmonary disease (other than controlled asthma), recreational or low-fit individuals, and athletes without expiratory flow limitation are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study enrolls trained male and female endurance athletes without asthma to receive salbutamol or placebo before standardized high-intensity exercise tests. Participants must have high aerobic capacity (V̇O2max >120% predicted), a BMI between 18 and 30 kg/m2, no recent smoking or cardiopulmonary disease, and will undergo measurements of expiratory flow limitation, FEV1, and exercise duration. The primary hypothesis is that salbutamol will increase exercise duration more in athletes who exhibit expiratory flow limitation (EFL) than in those who do not, and that females may show larger effects due to a higher prevalence of EFL. The goal is to determine whether a specific subgroup of non-asthmatic athletes can gain ventilatory or performance benefits from therapeutic β2-agonist use.
Why it matters
Potential benefit: If successful, the study could identify a subgroup of non-asthmatic endurance athletes who gain measurable breathing and performance benefits from salbutamol, helping to guide clinical care and sports screening policies.
How similar studies have gone: Most prior studies and systematic reviews show no ergogenic benefit of β2-agonists in non-asthmatics at therapeutic doses, though the idea that a small EFL-positive subgroup might benefit is plausible but unproven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aerobic capacity (V̇O2max) greater than 120% predicted * Body mass index (BMI) \> 18 and \< 30 kg/m2 * Ability to read and understand English * Currently training and/or competing in endurance sports (i.e. running or cycling) Exclusion Criteria: * Smoking history or currently smoking. Currently smoking is defined as regular use of cigarettes or cannabis at any point in the past year. History of smoking is defined as smoking more than 1 pack year for cigarettes or the equivalent in cannabis use measured as puffs per day / 200 (number of puffs in a pack of cigarettes). * Use of cannabis within the past 30 days or has a smoking history of at least 1 pack year. * Use of vaping devices or e-cigarettes in the past 30 days, or has used them more than 10 times in their lifetime. * History or current symptoms of cardiopulmonary disease (excluding controlled asthma) * Contraindications to exercise testing defined as anything that would prevent exercise under proper and safe conditions (e.g., a problem with the heart or lungs, muscle) * Neuromuscular or musculoskeletal condition
Where it's running
-
St. Paul's Hospital
Vancouver, British Columbia, Canada Recruiting
Study contacts
- Principal investigator: Jordan A Guenette, PhD — University of British Columbia
- Study coordinator: Satvir S Dhillon, MSc
- Email: satvir.dhillon@hli.ubc.ca
- Phone: 604-806-8835
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Chronic Respiratory Disease Participant Engagement
This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.
-
HB0056 in adults with moderate to severe asthma
This study tests HB0056 versus a placebo to see if it helps adults with moderate to severe asthma reduce rescue inhaler use and improve symptoms.
-
Tilrekimig (PF-07275315) for Severe Asthma: Aimed at Adults with Frequent Exacerbations
This study tests whether tilrekimig helps people with severe asthma who have had multiple flare-ups in the past year, by comparing it to a placebo given every four weeks.
-
Inhaled CHF10136 safety and pharmacokinetics in healthy adults and adults with asthma
This first-in-human study tests inhaled CHF10136 to see if it is safe and well tolerated, how it behaves in the body, and how it affects adults with asthma compared with placebo.
-
Biologics for Type 2 Inflammation in Asthma and COPD in Real World
This real-world study tests whether six biologic drugs can reduce flare-ups and improve symptoms in adults with asthma or COPD treated in routine care in China.
-
GSK5784283 vs placebo in uncontrolled asthma (PERSIST ASTHMA-2)
A new medicine called GSK5784283 is being tested to see if it lowers asthma flare-ups better than a placebo in people with uncontrolled asthma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.